NCT04747392已完成1 期
A Randomized, Open, Self-crossover, Single-dose Clinical Study to Compare Pharmacokinetic of Teriparatide Injection (SAL001) and the Original Drug FORSTEO in Healthy Chinese Adult Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- PK parameters: area under the plasma concentration time curve from-time zero to time t (AUC0-t)
研究概览
简要总结
This is a single-center, randomized, open label, single-dose, the original drug controlled, crossover design, two sequence, two periods, Phase Ⅰclinical study.
64 qualified subjects will be randomly assigned to two administration sequences (sequence A and sequence B) at the ratio of 1∶1, with 32 subjects in each sequence. Each period will be given subcutaneous injection once, and the washout period will be 72 hours, and each subject will be given subcutaneous injection twice. Sequence A: the test drug (SAL001) is injected in the first period, and the reference drug (FORSTEO) is injected in the second period. Sequence B: the reference drug (FORSTEO) is injected in the first period, and the test drug (SAL001) is injected in the second period.
If the geometric mean ratio (GMR) 90% confidence interval of the major pharmacokinetic indexes (AUC0-t, Cmax) for SAL001 and FORSTEO is between 80.00% and 125.00%, the two drugs are considered to be bioequivalent.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Those who volunteer to participate in the trial and sign the informed consent form.
- •Healthy Chinese male or female adults, the number of single sex volunteers is no less than 1/3, aged 20 to 50 years old (including the boundary value).
- •Males weighted ≥50kg, females weighted ≥45kg, body mass index (BMI) between 19-25 kg/m^2 (including boundary value), BMI= weight (kg)/height^2 (m^2).
排除标准
- •The existence of clinically significant diseases of heart, liver, lung, kidney, digestive tract, endocrine, metabolic and hematological systems.
- •history of parathyroid disease, or abnormal PTH with clinically significance judged by investigators.
- •Physical examination, laboratory examination, electrocardiogram (ECG), chest radiograph, abdominal ultrasound san(digestive system, urinary system), vital signs, etc., indicate that the subject has clinically significant abnormalities judged by the investigator.
- •Serum total calcium > upper limit of normal according to the normal range of the center, or previous hypercalcemia.
- •Hyperuricemia, or a previous history of gout, or abnormal blood uric acid with clinically significance judged by investigators at the time of screening.
- •Those with active urolithiasis.
- •Those who had received anti-osteoporosis agents (such as bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulator, parathyroid hormone and its analogues, strontium salts, active vitamin D and its analogues, vitamin K2, etc.) within 6 months before the first administration of the trial.
- •Those who had received oral or intravenous administration of glucocorticoids 3 months before the first administration of the trial.
- •Those who had taken any drug within 14 days before the first administration of the trial.
- •Allergies, such as allergic to two or more kinds of drugs or food; or known allergic to this drug components.
- •Alcoholism within 1 year before screening (drinking more than 3 times a day or more than 7 times a week, drinking 1 time =150mL red wine, or 360mL beer, or 50mL white wine), or a positive alcohol breath test.
- •A history of drug abuse within 1 year before screening, or a positive urine test for drugs at screening.
- •Those who were smoking more than 5 cigarettes a day within 3 months before screening.
- •Those who had participated in any other clinical trial within 3 months before the first administration of the trial.
- •Those who had blood donation or blood loss ≥400mL within 3 months before the first administration of the trial.
- •Those who do not agree to avoid the use of tobacco, alcohol or caffeinated beverages within 24 hours before the administration and during the trial, or do not agree to avoid strenuous exercise, or do not agree to avoid other factors affecting the absorption, distribution, metabolism and excretion of the drug.
- •Women who are pregnant or lactating, or who are positive for serum HCG, or who cannot/do not follow the instructions of investigators to take contraceptive measures approved by investigators during the study period.
- •Those who intend to give birth within 1 year.
- •Those with positive results of HBV surface antigen, or hepatitis C virus antibody positive, or Treponema pallidum antibody positive, or human immunodeficiency virus antibody positive.
- •Those with positive results of novel coronavirus nucleic acid test.
- •Those who are considered to be unsuitable for participation in this clinical study by investigators.
结局指标
主要结局
PK parameters: area under the plasma concentration time curve from-time zero to time t (AUC0-t)
时间窗: Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: peak plasma concentration (Cmax)
时间窗: Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
次要结局
- PK parameters: terminal elimination rate constant (λz)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: apparent total clearance (CL/F)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: apparent distribution volume (Vz/F)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: time to reach peak drug concentration (Tmax)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: half-life (t1/2)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PD parameters: area under the serum concentration time curve from-time zero to time t (AUC0-t)(Within 60 minutes before administration, and 120, 180, 240, 360, 480, 720 minutes after administration of Day 1 and Day 4)
- PK parameters: AUC extrapolated from Tmax to infinity in percentage of the total AUC (AUC%extrap)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: time to last measurable concentration (Tlast)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: mean residence time from time zero to infinity (MRT0-∞)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: area under the plasma concentration time curve from time zero to time infinity (AUC0-∞)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PK parameters: mean residence time from time zero to t (MRT0-t)(Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4)
- PD parameters: time to reach peak serum concentration (Tmax)(Within 60 minutes before administration, and 120, 180, 240, 360, 480, 720 minutes after administration of Day 1 and Day 4)
- PD parameters: area under the serum concentration time curve from time zero to time infinity (AUC0-∞)(Within 60 minutes before administration, and 120, 180, 240, 360, 480, 720 minutes after administration of Day 1 and Day 4)
- PD parameters: peak serum concentration (Cmax)(Within 60 minutes before administration, and 120, 180, 240, 360, 480, 720 minutes after administration of Day 1 and Day 4)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy VolunteersHealthyNCT02690727Rhizen Pharmaceuticals SA18
已完成
1 期
Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting ConditionsHealthy AdultsNCT03898193Pharmtechnology LLC34
已完成
1 期
Dose-Proportionality and Food Effect Study of TNX-102 SLHealthy SubjectsNCT04164719Tonix Pharmaceuticals, Inc.16
已完成
1 期
A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous AdministrationHealthy VolunteersNCT02573025Hoffmann-La Roche277
已完成
1 期
Single-dose AQ001S PK Study in Healthy VolunteersPharmacokineticsNCT05148312Aquilon Pharmaceuticals S.A.29